Drug Profile
SB 773812
Alternative Names: 773812; GW 773812Latest Information Update: 18 Jun 2015
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antipsychotics
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 18 Jun 2015 No recent reports on development identified - Phase-I for Schizophrenia in Spain and United Kingdom (PO)
- 18 Jun 2015 No recent reports on development identified - Phase-II for Schizophrenia in USA, Belgium, Costa Rica, Czech Republic, India, Peru and Russia (PO)
- 18 Mar 2011 Pharmacokinetics data from a phase I trial in Schizophrenia released by GlaxoSmithKline